At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas
In Brief
A Phase 2 clinical trial evaluating Zevalin, Carmustine, and 5 other interventions for Diffuse Large Cell Lymphoma and Lymphoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant.
Study Details
Timeline
Interventions
(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
300 mg/m\^2 by vein.
200 mg/m\^2 by vein every 12 hours.
200 mg/m\^2 by vein every 12 hours.
140 mg/m\^2 by vein.
Arm 1, Arm 2 = 250 mg/m\^2 by vein; Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant; Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.
Injection of stem cells (Autologous SCT)